Henan Provincial Key Laboratory of Brain-Targeted Bio-Nano Drugs published the latest GBM treatment research progress in ACS Nano and Journal of Controlled Release

Recently, the Henan Provincial Key Laboratory of Brain Targeted Bio-Nano Drugs has published 2 articles on glioma in the internationally renowned journals ACS Nano ( IF=15.

Brain-targeted biomimetic nanocarriers co-deliver Bcl-2/Bcl-xl and Mcl-1 inhibitors for in situ glioblastoma therapy

Glioblastoma (GBM) is the most common malignant glioma, which is difficult to treat and prone to recurrence

It is worth mentioning that the two inhibitors can still achieve synergistic anti-tumor efficacy when prepared into nano-drugs

The results were published in the journal ACS Nano as " Brain-Targeted Codelivery of Bcl-2/Bcl-xl and Mcl-1 Inhibitors by Biomimetic Nanoparticles for Orthotopic Glioblastoma Therapy " .

He Wenya, a postdoctoral researcher at Henan University, is the first author of the paper, and Professor Bing Yang and Associate Professor Zou Yan are the co-corresponding authors

Paper link: https://pubs.

Synergistic therapy of exosome-targeted heme oxygenase- 1 in temozolomide-resistant glioblastoma

Glioblastoma (GBM) is a highly lethal and recurrent brain cancer for which there is currently no fully effective treatment

This HMOX1- targeted BMSC -based exosome platform has the potential for clinical translation in glioma therapy and can also be applied to treat other HMOX1 -overexpressing brain diseases

Henan University postdoctoral researchers Fawad Ur Rehman , Liu Yang and master student Yang Qingshan are the co-first authors of the paper, and Professor Bing Yang and Professor Zheng Meng are the co-corresponding authors

Paper link: https://doi.

Website of Henan Provincial Key Laboratory of Brain Targeted Bio-Nano Drugs: https://bs.